Wednesday, March 22, 2023 1:04:20 AM
JMHO, but there's something wrong with his numbers on the 8K. There were already 10,000 shares of NC Preferred O/S at 12/31/22 with 20,000 A/S. In the 8K he acknowledges the 20,000 A/S, so 15,000 new shares exceed the A/S and there is no mention of a new authorization. Secondly, the Preferred shares were selling for $7.50 on 3/17/23. How can he justify 15,000 NC preferred shares for only $10,050 in debt?
He could probably justify a 9 or10% discount to $6.70 for 1,500 shares in exchange for cancellation of $10,050 in debt (as payment for the shares) or the full 15,000 shares for cancellation of $100,500 in debt, but that makes the O/S exceed the 20,000 A/S.
$.67 per NC Preferred share sets a bad precedent for future capital accumulation with preferred shares and would be contrary to his dilution comments in his CC's. This can't be correct. I'll be looking for an amended 8K unless someone here sees where I'm wrong. Anybody else?
He could probably justify a 9 or10% discount to $6.70 for 1,500 shares in exchange for cancellation of $10,050 in debt (as payment for the shares) or the full 15,000 shares for cancellation of $100,500 in debt, but that makes the O/S exceed the 20,000 A/S.
$.67 per NC Preferred share sets a bad precedent for future capital accumulation with preferred shares and would be contrary to his dilution comments in his CC's. This can't be correct. I'll be looking for an amended 8K unless someone here sees where I'm wrong. Anybody else?
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
